


An initiative of



BREAST CANCER DEBATE OF THE YEAR

THE HOTEL - Grand Ballroom 1st Floor

Boulevard de Waterloo 38, 1000 Brussels

Friday January 26, 2018

Program

An educational activity of the Breast Cancer Task Force of the BSMO

Organizing Committee:

Ahmad Awada (Institut Jules Bordet, Brussels), Hans Wildiers (UZ Leuven) and Peter Vuylsteke (CHU UCL Namur)

19:00-19:40 Welcome and buffet

19:40-19:45 Introduction:

Ahmad Awada (Institut Jules Bordet) and Hans Wildiers (UZ Leuven)

19:45-20:15 CDK4/6 inhibitor for all patients in the first-line setting of metastatic breast cancer?

In favour: Ahmad Awada, IJB (10 min)

Against: Guy Jerusalem, Liege (10 min)

Discussion: all (10 min)

20:15-20:45 All patients with HER2-positive breast should receive adjuvant pertuzumab in addition to trastuzumab

In favour: Peter Vuylsteke, Namur (10 min)

Against: Hannelore Denys, Gent (10 min)

Discussion: all (10 min)

20:45-21:15 Should all patients with TNBC be treated with platinum in the (neo) adjuvant setting?

In favour: Hans Wildiers, Leuven (10 min)

Against: Etienne Brain, Institut Curie - Paris (10 min)

Discussion: all (10 min)

21:15-21:45 Patients with TNBC without pCR should all receive adjuvant capecitabine

In favour: Jean-Luc Canon, Charleroi (10 min)

Against: Luc Dirix, Antwerp (10 min)

Discussion all (10 min)

21:45-22:00 Educational lecture : Results and perspectives of PARP inhibitors in the management of breast cancer - Christel Fontaine, (UZ Brussels)

22:00-22:15 Conclusions and take home messages: Peter Vuylsteke (CHU UCL Namur)

With the support of



NOVARTIS

